0 5.42005420055248E-05 0.000542005420054324 -0.00119241192411924 0 -0.00238482384823847 -0.00292682926829264 -0.00274905149051481
Sign Up Today X
Thanks for submitting the form.
Stockreport

GILD Signs Collaboration Agreement With Terray Therapeutics [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
govitecan-hziy), has been granted a second Breakthrough Therapy designation by the FDA for a lung cancer indication. The indicated population includes adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. Gilead's Trodelvy is currently approved for second-line or later metastatic triple-negative breast cancer (TNBC) patients in more than 50 countries and for certain patients with pre-treated HR+/HER2- metastatic breast cancer (MBC) in more than 40 countries, including the United States. The first Breakthrough Therapy designation was granted to Trodelvy for the TNBC indication in the United States. Benefits of the FDA's Breakthrough Therapy Designation Grant The FDA's Breakthrough Therapy designation is a process that speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when early clinical evidence suggests the drug may significantl [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

GILD Signs Collaboration Agreement With Terray Therapeutics [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
govitecan-hziy), has been granted a second Breakthrough Therapy designation by the FDA for a lung cancer indication. The indicated population includes adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. Gilead's Trodelvy is currently approved for second-line or later metastatic triple-negative breast cancer (TNBC) patients in more than 50 countries and for certain patients with pre-treated HR+/HER2- metastatic breast cancer (MBC) in more than 40 countries, including the United States. The first Breakthrough Therapy designation was granted to Trodelvy for the TNBC indication in the United States. Benefits of the FDA's Breakthrough Therapy Designation Grant The FDA's Breakthrough Therapy designation is a process that speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when early clinical evidence suggests the drug may significantl [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS